NANOG and ovarian cancer: We found that SGC0946 and EPZ004777 inhibited expression of DOT1L-targeted genes (MEIS1 and NANOG) in a dose-dependent manner, a finding which confirms the inhibitory effect of DOT1L activity in ovarian cancer cells (Supplementary Figure 20a).